These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26173839)

  • 1. Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.
    Arrieta O; De la Torre-Vallejo M; López-Macías D; Orta D; Turcott J; Macedo-Pérez EO; Sánchez-Lara K; Ramírez-Tirado LA; Baracos VE
    Oncologist; 2015 Aug; 20(8):967-74. PubMed ID: 26173839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
    Arrieta O; Vega-González MT; López-Macías D; Martínez-Hernández JN; Bacon-Fonseca L; Macedo-Pérez EO; Ramírez-Tirado LA; Flores-Estrada D; de la Garza-Salazar J
    Lung Cancer; 2015 Jun; 88(3):282-8. PubMed ID: 25882778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
    Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
    J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
    Cappuzzo F; Finocchiaro G; Grossi F; Bidoli P; Favaretto A; Marchetti A; Valente ML; Cseh A; Clementi L; Massey D; Santoro A
    J Thorac Oncol; 2015 Apr; 10(4):665-72. PubMed ID: 25514804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
    Passaro A; Di Maio M; Del Signore E; Gori B; de Marinis F
    Clin Lung Cancer; 2014 Jul; 15(4):307-12. PubMed ID: 24954231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
    Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
    Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hange-Shashin-to for preventing diarrhea during afatinib therapy].
    Yamaguchi O; Kawashima A; Shiono A; Maeno Y; Ishikawa R; Masumoto A; Utsugi H; Daito H; Okano T; Murayama Y; Kobayashi K
    Gan To Kagaku Ryoho; 2015 May; 42(5):581-3. PubMed ID: 25981651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib (BIBW 2992) development in non-small-cell lung cancer.
    Hirsh V
    Future Oncol; 2011 Jul; 7(7):817-25. PubMed ID: 21732753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
    Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
    Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].
    Iwata K; Ryota N; Hikita A; Sando M; Suzuki H; Tamiya M; Azuma Y; Tani E; Hamaguchi M; Tanaka A; Shiroyama T; Morishita N; Okamoto N; Futagami S; Hirashima T
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):967-72. PubMed ID: 26321711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib and lung cancer.
    Jain P; Khanal R; Sharma A; Yan F; Sharma N
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
    Köhler J; Schuler M
    Future Oncol; 2014 Mar; 10(4):533-40. PubMed ID: 24754585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
    Togashi Y; Masago K; Fujita S; Hatachi Y; Fukuhara A; Nagai H; Sakamori Y; Kim YH; Mio T; Mishima M
    Lung Cancer; 2011 Oct; 74(1):98-102. PubMed ID: 21377230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Afatinib (BIBW 2992)].
    Prim N; Fore M; Mennecier B
    Rev Pneumol Clin; 2014 Oct; 70(5):279-85. PubMed ID: 24878189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.